Arrowhead Sepera (544025)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 6.79% shows modest revenue expansion, not a shrinking business
• Latest quarter sales of ₹9 Cr implies annualised revenue of roughly ₹36 Cr, so the ₹32 Cr market cap is supported by a reasonable price-to-sales (~0.9x)
• ROCE is positive at 6.17%, indicating operations generate some return above break-even

Concerns

• Zero net profit in the latest quarter and a 73.24% profit decline leave no current earnings to support the valuation
• Piotroski F-Score of 4/9 points to weak financial health across profitability, leverage, and efficiency
• ROCE of 6.17% is low and likely below any meaningful cost of capital
• Missing book value, debt/equity, promoter holding, and ROE data make it impossible to assess margin of safety or governance
• No dividend means returns depend entirely on speculative price appreciation

AI Analysis

At ₹168.90, Arrowhead Sepera has a market capitalisation of just ₹32 Cr—a true microcap. The first thing that strikes me is the absence of earnings. The P/E is 0.00, and the latest quarter's net profit is ₹0 Cr. In Benjamin Graham's world, we do not pay a price for no earnings; we demand a measurable income stream. The profit figure has collapsed by 73.24%, while sales growth is only 6.79%. That tells me the company has lost pricing power or absorbed a severe cost shock. ROCE of 6.17% is barely enough to create value, and the Piotroski F-Score of 4 out of 9 flags weak financial health. There is also no dividend, so the investor gets zero immediate return. To make matters worse, critical information—book value, debt-to-equity, promoter holding, and ROE—is unavailable. Graham would say it is impossible to assess a margin of safety without such facts. The stock is trading at its 52-week high of ₹168.90, so the market has already moved optimistically. On the positive side, the business generated ₹9 Cr of sales in the latest quarter; annualised that is roughly ₹36 Cr against a ₹32 Cr market cap, so the price-to-sales is not extreme. But low sales multiples do not matter if profits are missing. I need to see several quarters of positive net profit, an improved ROCE, and a clean balance sheet before I can call this an investment. Until then, I will watch it from the sidelines. This is not a business with a demonstrated moat; it is a turnaround speculation dressed in a small-cap price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer